<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001415889-25-022288</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002082302</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001806952</issuerCik>        <issuerName>Lyell Immunopharma, Inc.</issuerName>

    <issuerCusips>
					<issuerCusipNumber>55083R203</issuerCusipNumber>
				</issuerCusips>

        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>201 Haskins Way</com:street1>
                    <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Explore Investments LLC</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1529054.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1529054.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1529054.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934 (as amended, the "Exchange Act") and based on an aggregate total of 23,328,390 shares of the common stock of Lyell Pharmaceuticals, Inc. (the "Issuer") outstanding as of March 31, 2026, as reported by the Issuer in its preliminary prospectus (the "Prospectus") (File No. 333-294884) dated April 3, 2026, incorporated in the Issuer's Form S-3 registration statement filed with the Securities and Exchange Commission (the "SEC") on April 3, 2026.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Jeffrey P. Bezos</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1529054.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1529054.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1529054.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.6</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>For purposes of Rule 13d-3 under the Exchange Act, all shares of the Issuer's common stock held by Explore may be deemed to be beneficially owned by Jeffrey P. Bezos as the sole member of Explore.

The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 23,328,390 shares of the Issuer's common stock outstanding as of March 31, 2026, as reported by the Issuer in the Prospectus.
</comments>

    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Lyell Immunopharma, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>201 Haskins Way, South San Francisco, CA, 94080.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>Explore Investments LLC, a Delaware limited liability company ("Explore")
Jeffrey P. Bezos, an Individual ("Mr. Bezos" and together with Explore, the "Reporting Persons")</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal business office of each of the Reporting Persons is:

P.O. Box 6470
Surfside, FL 33154</principalBusinessOfficeOrResidenceAddress>        <citizenship>Explore is formed in the State of Delaware.  Mr. Bezos is a citizen of the United States of America.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>Reference to "beneficial ownership" of securities for purposes of this amendment 1 to the statement on Schedule 13G (this "Statement") shall be understood to refer to beneficial ownership as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

As of March 31, 2026, the Reporting Persons may each be deemed to directly or indirectly beneficially own an aggregate 1,529,054 shares of the Issuer's common stock.

Explore is the direct holder of all the shares identified in the preceding paragraph.  For purposes of Rule 13d-3 under the Exchange Act, all of the aforementioned securities of the Issuer directly held by Explore may be deemed to be beneficially owned by Mr. Bezos as the sole member of Explore.  Notwithstanding, the filing of this Statement shall not be construed as an admission by Mr. Bezos, for purposes of Sections 13(d) or 13(g) of the Exchange Act or otherwise, as to beneficial ownership of the securities reported herein.
</amountBeneficiallyOwned>    <classPercent>As of March 31, 2026, the Reporting Persons were each deemed to directly or indirectly beneficially own an aggregate 6.6% of the Issuer's outstanding common stock.

The aforementioned percentage was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 23,328,390 shares of the Issuer's common stock outstanding as of March 31, 2026, as reported by the Issuer in its preliminary prospectus (the "Prospectus") (File No. 333-294884) dated April 3, 2026, incorporated in the Issuer's Form S-3 registration statement filed with the SEC on April 3, 2026.
</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Explore			0
Mr. Bezos		0</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Explore			1,529,054
Mr. Bezos		1,529,054</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Explore			0
Mr. Bezos		0</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Explore			1,529,054
Mr. Bezos		1,529,054</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>


	    <signatureInformation>
      <reportingPersonName>Explore Investments LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Paul Dauber</signature>
        <title>Paul Dauber/its Manager</title>
        <date>05/08/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Jeffrey P. Bezos</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Jeffrey P. Bezos</signature>
        <title>Jeffrey P. Bezos/an Individual</title>
        <date>05/08/2026</date>
      </signatureDetails>

    </signatureInformation>



  </formData>

    </edgarSubmission>
